Norverapamil Free Base | CAS# 67018-85-3 (free base) | calcium channel blocker

MedKoo Cat#: 414491 | Name: Norverapamil Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Norverapamil Free Base is the N-demethylated active metabolite of verapamil. Norverapamil is a calcium channel blocker. It is the main active metabolite of verapamil.

Chemical Structure

Norverapamil Free Base

CAS#67018-85-3 (free base)

Theoretical Analysis

MedKoo Cat#: 414491

Name: Norverapamil Free Base

CAS#: 67018-85-3 (free base)

Chemical Formula: C26H36N2O4

Exact Mass: 440.2675

Molecular Weight: 440.58

Elemental Analysis: C, 70.88; H, 8.24; N, 6.36; O, 14.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

67018-85-3 (free base) 67812-42-4 (HCl)

Synonym

Norverapamil Free Base

IUPAC/Chemical Name

5-((3,4-Dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile

InChi Key

UPKQNCPKPOLASS-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3

SMILES Code

N#CC(C(C)C)(C1=CC=C(OC)C(OC)=C1)CCCNCCC2=CC=C(OC)C(OC)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 440.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hamann SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002. PMID: 6362951. 2: Yao H, Wang C, Lu W, Li W, Jing W, Zhang J, Yang G, Zeng A. Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS. Xenobiotica. 2020 Jun;50(6):713-721. doi: 10.1080/00498254.2019.1682715. Epub 2019 Oct 31. PMID: 31633443. 3: Kim HJ, Choi JS. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharm Drug Dispos. 2005 Oct;26(7):295-300. doi: 10.1002/bdd.459. PMID: 16013069. 4: Hanke N, Türk D, Selzer D, Wiebe S, Fernandez É, Stopfer P, Nock V, Lehr T. A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies. Pharmaceutics. 2020 Jun 16;12(6):556. doi: 10.3390/pharmaceutics12060556. PMID: 32560124; PMCID: PMC7355632. 5: Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X. A semi-physiologically- based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302. doi: 10.1016/j.ejps.2013.07.012. Epub 2013 Jul 31. PMID: 23916407. 6: Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999 May;47(5):545-52. doi: 10.1046/j.1365-2125.1999.00923.x. PMID: 10336579; PMCID: PMC2014179. 7: Piovan D, Padrini R, Svalato Moreolo G, Magnolfi G, Milanesi O, Zordan R, Pellegrino PA, Ferrari M. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Ther Drug Monit. 1995 Feb;17(1):60-7. doi: 10.1097/00007691-199502000-00010. PMID: 7725379. 8: Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006 Oct;27(7):329-34. doi: 10.1002/bdd.512. PMID: 16892180. 9: Sun S, Wei Y, Wang H, Tang L, Deng B. Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. J Chromatogr Sci. 2021 Feb 15;59(3):289-296. doi: 10.1093/chromsci/bmaa098. PMID: 33333557. 10: Chu YQ, Wainer IW. Determination of the enantiomers of verapamil and norverapamil in serum using coupled achiral-chiral high-performance liquid chromatography. J Chromatogr. 1989 Dec 29;497:191-200. doi: 10.1016/0378-4347(89)80018-0. PMID: 2625456.